MedTrace Logo

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

NCT02151110 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

Conditions

  • Healthy Volunteer

Interventions

BIOLOGICAL

MEDI4920 3 mg

Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

BIOLOGICAL

MEDI4920 10 mg

Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

BIOLOGICAL

MEDI4920 30 mg

Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

BIOLOGICAL

MEDI4920 100 mg

Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

BIOLOGICAL

MEDI4920 300 mg

Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

BIOLOGICAL

MEDI4920 1000 mg

Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

BIOLOGICAL

MEDI4920 3000 mg

Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.

OTHER

Placebo

Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-27
Primary Completion
2016-05-09
Completion
2016-05-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02151110 on ClinicalTrials.gov